HCF Oncology Symposium
Wednesday, April 19, 2023
Southeast Community College Jack Huck Continuing Education Center
4:30 pm - 8:30 pm
The 2023 Oncology Symposium was a huge success! This year’s event featured two keynote speakers, Dr. Matthew Lunning & Madison Kaltenberger.
Stay tuned for information about next year's event. This educational opportunity is ideal for physicians, nurses, social workers, and advanced care practitioners.
CEU Credits • Vendor Booths • Dinner • Networking • Prizes
This program is offered at no cost to participants.
For sponsorship information, please reach out to Chris Blum at firstname.lastname@example.org.
Are you an event sponsor? You can make a sponsorship payment online by visiting the event registration site. Visit the ticketing tab and select your sponsorship level.
Matthew Lunning, D.O., FACP is an Associate Professor in the Division of Hematology/Oncology at UNMC. He received his medical degree from Des Moines University in 2006. Dr. Lunning completed his internal medicine residency at UNMC where he served as Chief Medical Resident. He completed his Hematology/Oncology fellowship and served as the Hematology Chief Fellow at Memorial Sloan-Kettering Cancer Center. Dr. Lunning returned to UNMC in 2013 and has been active in clinic research, research mentoring, education, and patient care. Dr. Lunning was the recipient of the Distinguish Scientist Award in 2019.
Madison Kaltenberger, MGC, CGC was born and raised in Nebraska. She graduated with her undergraduate degree from the University of Nebraska Lincoln and went on to get her master’s degree from UNMC where she was able to be a part of the inaugural class of their Genetic Counseling program. During her training she discovered her passion for preventative medicine and in June of 2021 she began working at Bryan as an oncology genetic counselor. She currently sees patients for genetic counseling at Cancer Partners of Nebraska and Bryan LifePointe. In her position, she is able to educate patients and their families on the subject of hereditary cancer risk and supporting them through the genetic testing process.